scholarly journals Abuse and Resilience in Relation to HAART Medication Adherence and HIV Viral Load Among Women with HIV in the United States

2014 ◽  
Vol 28 (3) ◽  
pp. 136-143 ◽  
Author(s):  
Sannisha Dale ◽  
Mardge Cohen ◽  
Kathleen Weber ◽  
Ruth Cruise ◽  
Gwendolyn Kelso ◽  
...  
Keyword(s):  
United States ◽  
Viral Load ◽  
Medication Adherence ◽  
The United States ◽  
Hiv Viral Load ◽  
Women With Hiv

scholarly journals The Effects of Viral Load Burden on Pregnancy Loss among HIV-Infected Women in the United States

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Jordan E. Cates ◽  
Daniel Westreich ◽  
Andrew Edmonds ◽  
Rodney L. Wright ◽  
Howard Minkoff ◽  
...  
Keyword(s):  
United States ◽  
Viral Load ◽  
Pregnancy Loss ◽  
Ethnically Diverse ◽  
The United States ◽  
Hiv Replication ◽  
Hiv Viral Load ◽  
Adjusted Risk ◽  
Hiv Rna ◽  
Risk Ratios

Background. To evaluate the effects of HIV viral load, measured cross-sectionally and cumulatively, on the risk of miscarriage or stillbirth (pregnancy loss) among HIV-infected women enrolled in the Women’s Interagency HIV Study between 1994 and 2013.Methods. We assessed three exposures: most recent viral load measure before the pregnancy ended, log10copy-years viremia from initiation of antiretroviral therapy (ART) to conception, and log10copy-years viremia in the two years before conception.Results. The risk of pregnancy loss for those with log10viral load >4.00 before pregnancy ended was 1.59 (95% confidence interval (CI): 0.99, 2.56) times as high as the risk for women whose log10viral load was ≤1.60. There was not a meaningful impact of log10copy-years viremia since ART or log10copy-years viremia in the two years before conception on pregnancy loss (adjusted risk ratios (aRRs): 0.80 (95% CI: 0.69, 0.92) and 1.00 (95% CI: 0.90, 1.11), resp.).Conclusions. Cumulative viral load burden does not appear to be an informative measure for pregnancy loss risk, but the extent of HIV replication during pregnancy, as represented by plasma HIV RNA viral load, predicted loss versus live birth in this ethnically diverse cohort of HIV-infected US women.

scholarly journals Time Spent with HIV Viral Load > 1500 Copies/mL Among Persons Engaged in Continuity HIV Care in an Urban Clinic in the United States, 2010–2015

2018 ◽  
Vol 22 (11) ◽  
pp. 3443-3450 ◽  
Author(s):  
Catherine R. Lesko ◽  
Bryan Lau ◽  
Geetanjali Chander ◽  
Richard D. Moore
Keyword(s):  
United States ◽  
Viral Load ◽  
The United States ◽  
Hiv Care ◽  
Hiv Viral Load ◽  
Urban Clinic

scholarly journals Protocol of the randomized control trial: the WiseApp trial for improving health outcomes in PLWH (WiseApp)

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Gabriella Flynn ◽  
Haomiao Jia ◽  
Nancy R. Reynolds ◽  
David C. Mohr ◽  
Rebecca Schnall
Keyword(s):  
United States ◽  
Viral Load ◽  
Medication Adherence ◽  
Randomized Control Trial ◽  
The United States ◽  
Self Management ◽  
Pill Bottle ◽  
Randomized Control ◽  
Fitness Tracker ◽  
Living With Hiv

Abstract Background Poor adherence to antiretroviral therapy (ART) is one of the primary barriers to viral load suppression. mHealth technology can help overcome challenges with ART adherence. This paper outlines the protocol for the WiseApp randomized control trial. The WiseApp contains real-time medication monitoring linking an electronic pill bottle and fitness tracker to the app, helping persons living with HIV (PLWH) self-manage their medication adherence and improve their overall quality of life. The primary objective of the trial is to test the effect of the WiseApp's medication adherence features on antiretroviral adherence in underserved PLWH in New York City. Methods This ongoing study is a two-arm randomized control trial. Participants are randomized 1:1 to the WiseApp intervention arm or the control arm at baseline and followed for 6 months. Eligibility criteria include: 18 years of age, have a diagnosis of HIV, speak and understand English or Spanish, live in the United States, own a smartphone, currently taking ART medications, and report the past 30 days adherence of 80% or less as measured using the Visual Analogue Scale (VAS), or have a viral load of over 400 copies/mL. The sample size for the trial is 200 people. All study participants receive the WiseApp, a CleverCap electronic pill bottle, and a fitness tracker. The intervention group also receives videos and health surveys centered on medication adherence and managing living with HIV as well as medication reminders. In contrast, the control group receives walk step reminders, videos, and surveys focused on overall wellness. Discussion The WiseApp Trial has the potential to improve HIV self-management applications, being one of the few randomized controlled trials of a mHealth medication adherence and HIV self-management application in the United States. The trial could also bring new opportunities for advancement in reaching economically disenfranchised and underserved populations in the United States. The real-time monitoring of the WiseApp has the potential to help providers initiate interventions to help patients resume treatment before drug resistance begins. Trial registration This trial was registered with ClinicalTrials.gov (NCT03205982) on July 2, 2017.

Erenumab patient characteristics, medication adherence, and treatment patterns in the United States

2021 ◽  
Vol 61 (4) ◽  
pp. 590-602
Author(s):  
Dionne M. Hines ◽  
Shweta Shah ◽  
Jasjit K. Multani ◽  
Rolin L. Wade ◽  
Dawn C. Buse ◽  
...  
Keyword(s):  
United States ◽  
Medication Adherence ◽  
Patient Characteristics ◽  
The United States ◽  
Treatment Patterns

Socioeconomic, Psychosocial, and Clinical Factors Associated With Employment in Women With HIV in the United States

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jenni M. Wise ◽  
Andres Azuero ◽  
Deborah Konkle-Parker ◽  
James L. Raper ◽  
Karen Heaton ◽  
...  
Keyword(s):  
United States ◽  
The United States ◽  
Clinical Factors ◽  
Factors Associated ◽  
Women With Hiv

scholarly journals Moderating Factors in an Anti-stigma Intervention for African American Women with HIV in the United States: A Secondary Analysis of the UNITY Trial

2019 ◽  
Vol 23 (9) ◽  
pp. 2432-2442 ◽  
Author(s):  
Katrin E. Fabian ◽  
David Huh ◽  
Christopher G. Kemp ◽  
Paul E. Nevin ◽  
Jane M. Simoni ◽  
...  
Keyword(s):  
United States ◽  
African American ◽  
African American Women ◽  
Secondary Analysis ◽  
The United States ◽  
American Women ◽  
Moderating Factors ◽  
Women With Hiv
Sign in / Sign up

Export Citation Format

Share Document